This may be effective for patients who are responsive to immune checkpoint therapy, as a study in melanoma demonstrated that responding patients have higher CD8+ T-cells pre-treatment, and also an increased proliferation of CD8+ T-cells following immune checkpoint therapy [76,77]. The gene discussed is CD8A; the disease is melanoma.